NASDAQ:PTI - Proteostasis Therapeutics Stock Price, Price Target & More

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Proteostasis Therapeutics Inc (NASDAQ:PTI) posted its earnings results on Wednesday, May, 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.21. Proteostasis Therapeutics had a negative return on equity of 101.44% and a negative net margin of 1,052.11%. View Proteostasis Therapeutics' Earnings History.

4 brokers have issued 1-year target prices for Proteostasis Therapeutics' shares. Their predictions range from $5.00 to $25.00. On average, they expect Proteostasis Therapeutics' stock price to reach $13.25 in the next twelve months. View Analyst Ratings for Proteostasis Therapeutics.

Some companies that are related to Proteostasis Therapeutics include GTX (GTXI), Unum Therapeutics (UMRX), American Brivision (Holding) (ABVC), Achillion Pharmaceuticals (ACHN), Savara (SVRA), Tyme Technologies (TYME), Seres Therapeutics (MCRB), Corvus Pharmaceuticals (CRVS), MediciNova (MNOV), Arbutus Biopharma (ABUS), Aquinox Pharmaceuticals (AQXP), Syros Pharmaceuticals (SYRS), Kala Pharmaceuticals (KALA), Paratek Pharmaceuticals (PRTK) and Innate Pharma (IPHYF).

(PTI) raised $51 million in an IPO on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Media headlines about PTI stock have been trending somewhat positive this week, according to Accern. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Proteostasis Therapeutics earned a media sentiment score of 0.16 on Accern's scale. They also gave headlines about the company an impact score of 46.07 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Proteostasis Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bailard Inc. (1.49%), Lord Abbett & CO. LLC (1.33%), DAFNA Capital Management LLC (0.74%), Millennium Management LLC (0.59%), Franklin Resources Inc. (0.32%) and Doheny Asset Management CA (0.19%). Company insiders that own Proteostasis Therapeutics stock include Cormorant Asset Management, Ll, Enterprise Associates 12 New, Fmr Llc, Franklin M Berger and Meenu Chhabra. View Institutional Ownership Trends for Proteostasis Therapeutics.

PTI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Franklin Resources Inc. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Proteostasis Therapeutics.

PTI stock was acquired by a variety of institutional investors in the last quarter, including Bailard Inc., Lord Abbett & CO. LLC, DAFNA Capital Management LLC, Doheny Asset Management CA, Tibra Equities Europe Ltd, Barclays PLC, Bayesian Capital Management LP and Element Capital Management LLC. Company insiders that have bought Proteostasis Therapeutics stock in the last two years include Cormorant Asset Management, Ll, Enterprise Associates 12 New, Franklin M Berger and Meenu Chhabra. View Insider Buying and Selling for Proteostasis Therapeutics.

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PTI stock can currently be purchased for approximately $3.10.

Proteostasis Therapeutics has a market capitalization of $105.72 million and generates $5.34 million in revenue each year. The company earns $-59,430,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Proteostasis Therapeutics employs 52 workers across the globe.

Proteostasis Therapeutics' mailing address is 80 GUEST STREET 5TH FLOOR, BOSTON MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]